Interviews

Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.

Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an audio interview.

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.

Urologists at the Cleveland Clinic in Ohio and Abu Dhabi collaborated successfully to perform the first transcontinental robotic-assisted focal therapy for prostate cancer using EDAP’s Focal One HIFU robotic system. The procedure served as proof of concept for future teleprocedures. EDAP’s CEO Ryan Rhodes told Medtech Insight other hospitals are also showing interest in this type of collaboration.

Egg Medical is ramping up efforts to expand international sales of its EggNest scatter radiation protection system to shield X-ray procedure room staff without disrupting workflow. Medtech Insight sat down with Bob Wilson, Egg Medical’s CEO, to discuss the various EggNest systems, marketing opportunities and the competitive landscape.

In a video interview, Wockhardt chairman Habil Khorakiwala talks about global commercial and manufacturing plans for superbug-busting novel antibiotics and developments such as proposed US tariffs and the Windsor framework that could impact its markets.

Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.

Discover Henlius’ groundbreaking achievements, and their mission to deliver affordable, innovative drugs worldwide through strategic partnerships.

Discover Henlius’ groundbreaking achievements, and their mission to deliver affordable, innovative drugs worldwide through strategic partnerships.

Medtech Insight asked three leading AI experts, Verily’s Andrew Trister, Ferrum Health’s Pelu Tran and Hologic’s Jennifer Schneiders, to offer their perspectives on the future of AI in health care.

The Swiss giant’s blockbuster gene therapy is currently only administered intravenously into patients with spinal muscular atrophy under two years of age. Its intrathecal candidate, called OAV-101, has just passed a Phase III test which could expand its use in children and young adults.